The Manchester Molecular Pathology Innovation Centre (MMPathIC) launched in October 2015 after The University of Manchester received £2.9 million from the Medical Research Council (with co-funding from the Engineering and Physical Sciences Council) to develop new tests based on molecular pathology techniques.
We provide an environment to facilitate the translation of stratified medicine and biomarker research into usable tests that can be implemented within the NHS.
Our objectives are:
- targeted discovery, development and validation of novel biomarkers and engineering-based technologies supportive of molecular pathology;
- translation into molecular pathology tests, based on a solid evaluation of a value proposition;
- taking technology into clinical laboratories and commercial settings;
- education and awareness;
- catalysing interactions between organisations/individuals that further MMPathIC's goals.
Delivering novel diagnostics and molecular pathology tests to the clinic or market involves a series of steps, forming the development pathway, to establish the analytical accuracy, clinical and cost effectiveness, and clinical utility of a novel marker.
MMPathIC works with researchers and companies who are at different steps of this pathway. To ensure the greatest likelihood of achieving MMPathIC's vision of delivering new tests to the clinic, all potential projects are evaluated for their likely value proposition.
The National Institute for Health and Clinical Excellence evaluates medical technologies and diagnostics, and makes recommendations as to whether they should be used in the NHS. A key assessment criterion for a new technology is its value proposition.
The value proposition asks whether the new technology does the same thing at a lower cost, or if it is better for the same price. Within the MMPathIC pipeline approach, this is evaluated at the first stages as, without fulfilling this, a new product is unlikely to be adopted by the NHS.
Please get in touch if you have any ideas for collaboration.
Company Details
- Founded
- -
- Address
- The University Of Manchester, Nelson Street, Manchester,greater Manchester M13 9nq,united Kingdom
- Industry
- Higher Education
- NAICS
-
Colleges, Universities, and Professional Schools
- Keywords
- Biomarker discovery, Precision medicine, Molecular pathology, Health economics, Bioinformatics.
- HQ
- Manchester, Greater Manchester
Manchester Molecular Pathology Innovation Centre Questions
Manchester Molecular Pathology Innovation Centre's website is http://www.manchester.ac.uk/mmpathic
Manchester Molecular Pathology Innovation Centre's LinkedIn profile is https://uk.linkedin.com/company/manchester-molecular-pathology-innovation-centre
Manchester Molecular Pathology Innovation Centre's industry is
Higher Education
Manchester Molecular Pathology Innovation Centre's top competitors are
Aeonox Pathology,
Primary Pathology,
Glycoscoredx Ltd,
Rainbow Labs,
Inexia,
Uk Neqas For Immunocytochemistry & In Situ Hybridisation,
Bloodrun Evs,
Kcl Pathology Society,
Avian Pathology And Diagnostics Consultancy,
Afos Medical.
Manchester Molecular Pathology Innovation Centre's categories are Higher Education
Manchester Molecular Pathology Innovation Centre's founding year is 2015
